Synchron
Synchron is an Endovascular BCI company founded in 2012 and based in Brooklyn, United States. It has raised $345M in total funding, most recently a Series D in 2025 at a $1B valuation.
Delivers a motor neuroprosthesis via the jugular vein into brain blood vessels, avoiding open brain surgery. Stentrode system implanted in multiple patients in U.S. and Australia. Raised $200M Series D in November 2025, bringing total funding to $345M.
First to receive FDA Breakthrough Device designation for a permanently implantable BCI and first to implant a patient in the U.S., defining the minimally-invasive endovascular category.
synchron.com ↗·Endovascular BCI·
United States·private 
